Most Viewed Articles - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Most Viewed Articles

Hospira Acquires Orchid's API Manufacturing and R&D Facilities

July 9, 2014

Hospira acquires assets from Orchid Chemicals & Pharmaceuticals for $218 million.

EMA Revises Guidance on Advanced Therapies

July 1, 2014

European Medicines Agency clarifies advanced-therapy medicinal products classification.

FDA Outlines Guidance and Rules for Compounding Drug Products

July 1, 2014

FDA releases guidance documents and rules on requirements for compounding human drug products.

BMS Recalls Coumadin Vials Due to Particulate Matter

July 1, 2014

Bristol-Myers Squibb issues a voluntary US recall of Coumadin (warfarin sodium) for injection due to presence of particulate matter.

FDA Issues Warning Letter to GSK Biologicals

June 26, 2014

GSK Biologicals receives warning about cGMP compliance issues at its Quebec facility.

National Bioscience Report Reveals Positive Trends for Bioscience Industry

June 25, 2014

According to the National Bioscience Report, the US bioscience industry is on course for continued growth.

Abbott to Acquire Russia's Veropharm

June 25, 2014

Abbott will acquire a controlling interest in the Russian pharmaceutical manufacturer Veropharm.

FDA Issues Warning Letter to API Manufacturer Apotex Pharmachem India

June 18, 2014
PTSM: Pharmaceutical Technology Sourcing and Management

FDA inspection found cGMP violations in the Bangalore, India API manufacturing facility.

FDA Issues Warning Letter to Tianjin Zhongan Pharmaceutical

June 18, 2014
PTSM: Pharmaceutical Technology Sourcing and Management

FDA cites cGMP violations for API manufacturing at a facility in Tianjin, China.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
33%
Breakthrough designations
17%
Protecting the supply chain
50%
Expedited reviews of drug submissions
0%
More stakeholder involvement
0%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Click here